Scientists have discovered a hidden weakness shared by hundreds of cancer mutations, which could potentially lead to new treatments. The weakness may be exploitable by existing FDA-approved drugs, and research suggests it could be relevant to various types of cancer, including brain tumors and small cell neuroendocrine cancers. However, the exact nature and scope of the discovery, as well as its potential applications, are not entirely clear from the available reports.